HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Glenn W. Laub Mark S. Adkins Javier Fernandez William A. Anderson Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Laub, G. W. Articles by McGrath, L. B. Search for Related Content PubMed PubMed Citation Articles by Laub, G. W. Articles by McGrath, L. B.

Ann Thorac Surg 1992;54:826-831
© 1992 The Society of Thoracic Surgeons

---

Articles

Cryopreserved allograft veins as alternative coronary artery bypass conduits: Early phase results

^a Division of Cardiothoracic Surgery, Deborah Heart and Lung Center, Browns Mills, New Jersey, USA
^b Department of Surgery, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

^_* Address reprint requests to Dr Laub, Deborah Heart and Lung Center, Browns Mills, NJ 08015.

Traditional autologous conduits are sometimes unavailable or unsuitable to permit total revascularization during coronary artery bypass grafting. In these patients the results of using nonautologous alternative conduits has been disappointing. Encouraged by the excellent longterm results seen with cryopreserved allograft valves, a clinical protocol was developed to evaluate the use of a commercially cryopreserved allograft saphenous vein (CPV). Our protocol consisted of using CPV when left internal mammary arteries and autologous saphenous vein grafts were unavailable or unsuitable for complete revascularization. Blood group (ABO) typed CPVs were thawed and implanted as required using standard surgical techniques. From December 1989 through June 1991, 19 of 1,602 patients who underwent coronary revascularization had CPVs implanted (1.2%). There were no operative deaths. An attempt was made to evaluate the patency of all grafts with coronary arteriography or ultrafast computed tomographic scans. Fourteen patients were available for patency evaluation. Patency rate in the 14 patients studied at a mean of 7 ± 2 months (range, 2 to 16 months) were: internal mammary artery, 93% ([equation]); saphenous vein graft, 80% ([equation]); and CPV, 41% ([equation]). The patency of the CPV was significantly less than the patency rate for the saphenous vein and internal mammary artery (p = 0.004). We conclude that the short-term patency rate of CPVs is inferior to that of autologous vessels. Due to its poor patency, we recommend that CPV should only be used when no other autologous conduit is available.

This article has been cited by other articles:

				M. Desai, A. M. Seifalian, and G. Hamilton Role of prosthetic conduits in coronary artery bypass grafting Eur J Cardiothorac Surg, August 1, 2011; 40(2): 394 - 398. [Abstract] [Full Text] [PDF]

				S. L. M. Dahl, A. P. Kypson, J. H. Lawson, J. L. Blum, J. T. Strader, Y. Li, R. J. Manson, W. E. Tente, L. DiBernardo, M. T. Hensley, et al. Readily Available Tissue-Engineered Vascular Grafts Science Translational Medicine, February 2, 2011; 3(68): 68ra9 - 68ra9. [Abstract] [Full Text] [PDF]

				Y. J. Woo and T. J. Gardner Myocardial Revascularization with Cardiopulmonary Bypass Card. Surg. Adult, January 1, 2003; 2(2003): 581 - 607. [Full Text]

				H. R. Laube, J. Duwe, W. Rutsch, and W. Konertz Clinical experience with autologous endothelial cell-seeded polytetrafluoroethylene coronary artery bypass grafts J. Thorac. Cardiovasc. Surg., July 1, 2000; 120(1): 134 - 141. [Abstract] [Full Text] [PDF]

				K. A. Eagle, R. A. Guyton, R. Davidoff, G. A. Ewy, J. Fonger, T. J. Gardner, J. P. Gott, H. C. Herrmann, R. A. Marlow, W. C. Nugent, et al. ACC/AHA guidelines for coronary artery bypass graft surgery: A report of the American College of Cardiology/ American Heart Association task force on Practice Guidelines (Committee to revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery) J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1262 - 1347. [Full Text] [PDF]

				T. V. Bilfinger, A. R. Hartman, Y. Liu, H. I. Magazine, and G. B. Stefano Cryopreserved Veins in Myocardial Revascularization: Possible Mechanism for Their Increased Failure Ann. Thorac. Surg., April 1, 1997; 63(4): 1063 - 1069. [Abstract] [Full Text]

				J. R. Glasson, D. R. James, and J. T. Mehigan Rapidly Expanding Aneurysms in Cryopreserved Vein Grafts: Case Reports Vascular and Endovascular Surgery, May 1, 1996; 30(3): 261 - 267. [Abstract] [PDF]

				G. Bogats, E. Kertesz, M. Katona, A. Toszegi, and G. S. Kovacs Modified Blalock-Taussig Shunt Using Allograft Saphenous Vein: Six Years' Experience Ann. Thorac. Surg., January 1, 1996; 61(1): 58 - 62. [Abstract] [Full Text]

				L. S. Bambang, J. P. Mazzucotelli, M. Moczar, F. Beaujean, and D. Loisance EFFECTS OF CRYOPRESERVATION ON THE PROLIFERATION AND ANTICOAGULANT ACTIVITY OF HUMAN SAPHENOUS VEIN ENDOTHELIAL CELLS J. Thorac. Cardiovasc. Surg., October 1, 1995; 110(4): 998 - 1004. [Abstract] [Full Text]

				H. B. Barner Allogenic vein as a conduit for coronary artery bypass Ann. Thorac. Surg., November 1, 1992; 54(5): 817 - 817. [Abstract] [PDF]